Literature DB >> 23622394

Niemann-Pick diseases.

Marie T Vanier1.   

Abstract

The Niemann-Pick disease group is now divided into two distinct entities: (1) acid sphingomyelinase-deficient Niemann-Pick disease (ASM-deficient NPD) resulting from mutations in the SMPD1 gene and encompassing type A and type B as well as intermediate forms; (2) Niemann-Pick disease type C (NP-C) including also type D, resulting from mutations in either the NPC1 or the NPC2 gene. Both Niemann-Pick diseases have an autosomal recessive inheritance and are lysosomal lipid storage disorders, with visceral (type B) or neurovisceral manifestations. The clinical knowledge is updated taking into account recent surveys in large cohort of patients, particularly for type B and type C. The diagnosis of NP-C is often delayed due to the wide spectrum of clinical phenotypes. Systemic manifestations, if present, always precede onset of neurological manifestations. Most common neurological signs are vertical supranuclear gaze palsy, cerebellar ataxia, dysarthria, dysphagia, and progressive dementia. Cataplexy, seizures, and dystonia are other common features of NP-C. For both ASM-deficient NPD and NP-C, strategies for laboratory diagnosis of patients and prenatal diagnosis are discussed. Recent progress towards enzyme replacement therapy in type B patients and management of the neurological disease in type C patients are finally highlighted.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23622394     DOI: 10.1016/B978-0-444-59565-2.00041-1

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  58 in total

1.  FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts.

Authors:  Jason Newton; Nitai C Hait; Michael Maceyka; Alexandria Colaco; Melissa Maczis; Christopher A Wassif; Antony Cougnoux; Forbes D Porter; Sheldon Milstien; Nicholas Platt; Frances M Platt; Sarah Spiegel
Journal:  FASEB J       Date:  2017-01-12       Impact factor: 5.191

Review 2.  The potential of histone deacetylase inhibitors in Niemann - Pick type C disease.

Authors:  Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  FEBS J       Date:  2013-09-23       Impact factor: 5.542

3.  Genetic and pharmacological evidence implicates cathepsins in Niemann-Pick C cerebellar degeneration.

Authors:  Chan Chung; Prasanth Puthanveetil; Daniel S Ory; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2016-01-28       Impact factor: 6.150

Review 4.  Do heterozygous mutations of Niemann-Pick type C predispose to late-onset neurodegeneration: a review of the literature.

Authors:  Susanne A Schneider; Sabina Tahirovic; John Hardy; Michael Strupp; Tatiana Bremova-Ertl
Journal:  J Neurol       Date:  2019-11-07       Impact factor: 4.849

5.  Targeting defective sphingosine kinase 1 in Niemann-Pick type C disease with an activator mitigates cholesterol accumulation.

Authors:  Jason Newton; Elisa N D Palladino; Cynthia Weigel; Michael Maceyka; Markus H Gräler; Can E Senkal; Ricardo D Enriz; Pavlina Marvanova; Josef Jampilek; Santiago Lima; Sheldon Milstien; Sarah Spiegel
Journal:  J Biol Chem       Date:  2020-05-08       Impact factor: 5.157

Review 6.  The Extending Spectrum of NPC1-Related Human Disorders: From Niemann-Pick C1 Disease to Obesity.

Authors:  Amel Lamri; Marie Pigeyre; William S Garver; David Meyre
Journal:  Endocr Rev       Date:  2018-04-01       Impact factor: 19.871

Review 7.  Cataplexy and sleep disorders in Niemann-Pick type C disease.

Authors:  Sona Nevsimalova; Vera Malinova
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

8.  Cirrhosis and liver failure: expanding phenotype of Acid sphingomyelinase-deficient niemann-pick disease in adulthood.

Authors:  Olivier Lidove; Frédéric Sedel; Frédéric Charlotte; Roseline Froissart; Marie T Vanier
Journal:  JIMD Rep       Date:  2014-04-10

Review 9.  Nuclear lipid mediators: Role of nuclear sphingolipids and sphingosine-1-phosphate signaling in epigenetic regulation of inflammation and gene expression.

Authors:  Panfeng Fu; David L Ebenezer; Alison W Ha; Vidyani Suryadevara; Anantha Harijith; Viswanathan Natarajan
Journal:  J Cell Biochem       Date:  2018-05-08       Impact factor: 4.429

10.  Vestibular function in patients with Niemann-Pick type C disease.

Authors:  Tatiana Bremova; Siegbert Krafczyk; Stanislavs Bardins; Jörg Reinke; Michael Strupp
Journal:  J Neurol       Date:  2016-08-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.